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Endosomal Escape of Antisense Oligonucleotides
Internalized by Stabilin Receptors Is Regulated
by Rab5C and EEA1 During Endosomal Maturation
Colton M. Miller,1 W. Brad Wan,2 Punit P. Seth,2 and Edward N. Harris1
Second-generation (Gen 2) Antisense oligonucleotides (ASOs) show increased nuclease stability and affinity for
their RNA targets, which has translated to improved potency and therapeutic index in the clinic. Gen 2 ASOs
are typically modified using the phosphorothioate (PS) backbone modification, which enhances ASO interac-
tions with plasma, cell surface, and intracellular proteins. This facilitates ASO distribution to peripheral tissues
and also promotes cellular uptake after injection into animals. Previous work identified that Stabilin receptors
specifically internalize PS-ASOs in the sinusoidal endothelial cells of the liver and the spleen. By modulating
expression of specific proteins involved in the trafficking and maturation of the endolysosomal compartments,
we show that Rab5C and EEA1 in the early endosomal pathway, and Rab7A and lysobisphosphatidic acid in the
late endosomal pathway, are important for trafficking of PS-ASOs and facilitate their escape from en-
dolysosomal compartments after Stabilin-mediated internalization. In conclusion, this work identifies key rate-
limiting proteins in the pathway for PS-ASO translocation and escape from the endosome.
Keywords: endosome maturation, endosome escape, antisense oligonucleotide, Stabilin, ASO
Introduction
Oligonucleotide therapeutics have made rapidprogress in clinical settings, [1] but the precise path-
ways by which these agents enter cells and escape from en-
dolysosomal compartments to exert antisense effects are just
starting to be understood [1,2]. Antisense oligonucleotides
(ASOs) are short (*16–20 bp), chemically modified nucleic
acids, which utilize Watson–Crick base pairing for hybrid-
izing to their cognate RNA in cells. Second-generation ASOs
are typically modified using the phosphorothioate (PS) back-
bone and 2¢ modifications of the ribose sugar, which enhance
ASO stability in biological fluids [3]. PS-ASOs can exert their
biological effects through a variety of antisense mechanisms
based on the chemical composition of the oligonucleotide. For
example, DNA gapmer PS-ASOs promote degradation of their
target RNA by RNase H-mediated hydrolysis while uniformly
modified MOE PS-ASOs can modulate RNA splicing [4].
Understand the biological mechanisms responsible for bind-
ing, internalizing, and trafficking PS-ASOs are currently areas
of active investigation. Recent work showed that Annexin A2
facilitates transport of PS-ASOs from early endosomes to late
endosomes (LE) and is involved in the release of ASOs from
late endosomal compartments in several common cell lines,
such as A431, HEK293, and HepG2 [5].
PS-ASOs were recently shown to be rapidly internalized
by clathrin-mediated endocytosis by a class of membrane-
bound scavenging receptor proteins known as the Stabilin
receptors in the liver sinusoidal endothelial cells, a site for
the clearance of many blood-borne matrix and synthetic
molecules [6]. Stabilin receptors (Stabilin-1 and Stabilin-2)
bind to and internalize a host of negatively charged poly-
mers, ranging from smaller, *20 nucleotide PS-ASOs [6]
(both Stabilin receptors), to large glycosaminoglycans, such
as *30 kDa unfractionated heparin and 3–400 kDa hyalur-
onan (Stabilin-2 only) [7,8]. Stabilin-2, also known as the
Hyaluronic-Acid Receptor for Endocytosis (HARE), has two
distinctly expressed isoforms in native tissue,190-kDa and
315-kDa [9]. The 190-kDa isoform is a truncated version of
the full 315-kDa isoform, but retains full functionality for
binding and endocytosis [10]. Both isoforms have been
shown to be able to internalize PS-ASOs equally; however,
for this work, we decided to utilize recombinant cells over-
expressing the 190-kDa isoform. The use of this cell line is
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relevant based on the 1:1 expression ratio of both Stabilin-2
isoforms in native tissues [11].
Our initial efforts of this work focused on early endosomal
antigen 1 (EEA1), which is a peripheral membrane associ-
ated protein found in the early endosome, containing zinc-
dependent binding motifs [12]. This protein was selected
based on its role in early endosomal transport by localizing to
the early endosome with Rab5 and phosphatidylinositol (3)P-
kinase [13]. Rab5 has three distinct isoforms, Rab5A, B, and
C, which all bind to EEA1, however, Rab5C has distinct
functional differences compared to Rab5A and Rab5B. Rab5
isoforms have shown preferential differences to specific
protein targets, along with identification of differing roles in
functionality such as EGFR degradation [14]. Rab5C binding
to EEA1 confers directionality of the endosomes from early
to late stages, by serving as a regulatory element for SNARE
protein family members in EE fusion and maturation to LEs
[13,15]. The role of Rab7A in altering PS-ASO activity was
also evaluated, as this protein is an activator in endosomal
maturation, lysosome biogenesis, fusion, and morphological
changes of LEs, as well as a variety of interacting partners
[16–18]. One LE-specific resident of particular interest is
lysobisphosphatidic acid (LBPA) (Fig. 1). LBPA is an un-
common lipid that is enriched in the LE [19], and has shown
to be involved in controlling cholesterol levels in LEs [20].
Recent work has suggested that LPBA is an essential com-
ponent for PS-ASO escape in the LE [21]. Taken together,
manipulation of these endosomal molecules may increase the
understanding of PS-ASO activity after internalization by
Stabilin-1 and -2.
Materials and Methods
Cell lines
Stabilin-2 (190-HARE) and empty vector cell lines were
generated as previously described [9,10]. Briefly, the cDNA
of interest was cloned into pcDNA5/FRT/V5–6xHIS-TOPO
(Life Technologies) and stably transfected in HEK293 Flp-In
cells within the FRT site to eliminate off-target effects of
gene disruption (Life Technologies). Cell lines were grown
and maintained in DMEM containing 8% FBS supplemented
with 50mg/mL Hygromycin B.
Oligonucleotide synthesis and delivery
Phosphorothioate PS-ASOs were synthesized using a
standard phosphoramidite chemistry by using a DNA syn-
thesizer at Integrated DNA Technologies (Iowa City, IA) or
at Ionis Pharmaceuticals (Carlsbad, CA) againstMalat-1. PS-
ASOs were delivered to cultured cells utilizing standardized
gymnotic conditions. PS-ASOs were added to standard
Dulbecco’s modified Eagle’s medium (DMEM) without se-
rum, and diluted to 1mM.One hundredmicroliters of medium
was added to 900mL of DMEM with 8% FBS to reach a final
concentration of 0.1 mM of PS-ASO. The PS-ASO used for
this study was GCTTCAGTCATGACTTCCTT, which tar-
gets the long noncoding RNAMalat-1 and previously verified
[6]. The PS-ASO was fully modified using the PS backbone
and the bold letters indicate 2¢-Methoxyethyl (MOE) RNA
nucleotides. The biotinylated ASO (bASO) used for this study
wasGCTTCAGTCATGACTTCCTT (Ionis AA7141) with a
modified 5¢ terminus containing a piperidine linker to accept
biotin-NHS. Details of the synthesis and purification proce-
dures are in supplemental materials (Supplementary Fig. S1;
Supplementary Data are available online at www.liebertpub
.com/nat).
siRNA delivery
Stabilin-2 190-kDa cells were plated in 24-well dishes and
grown to 50% confluency followed by transfection of 5 pmol
siRNAs in duplicate wells, giving a final concentration of
2.5 pmol siRNA per well. siRNAs were used against specific
protein targets and transfection was facilitated by RNAiMAX
Lipofectamine (Life Technologies). siRNAs were ordered
FIG. 1. Proposed mech-
anism of late endosomal PS-
ASO escape by internalization
through Stabilin receptors. Key
interactor molecules high-
lighted for escape in both
early and late endosomes.
PS-ASO, phosphorothioate–
antisense oligonucleotide.
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from Silencer Select (Ambion) for each protein target in the
pathway. The sense sequences are: EEA1–5¢-GCUAAGUU
GCAUUCCGAAtt-3¢, Rab7A- 5¢-GAGCUGACUUUCUGA
CCAAtt-3¢, Rab5A- 5¢-GCAAGCAAGUCCUAACAUUtt-3¢,
Rab5B- 5¢-GGAGCGAUAUCACAGCUUAtt-3¢, and Rab5C-
5¢-GGACAGGAGCGGUAUCACA-3¢. Negative/scrambled
control was prestocked with the catalog number 4390843.
Purification of RNA and qPCR analysis
Cells were plated in 24-well dishes and treated with siRNAs
above when cells were at 50% confluency. After 24 h of in-
cubationwith siRNAs, cells were treated with 0.1mMPS-ASO
against Malat-1, and incubated for 24 h. After incubation of
PS-ASOs, cells were lysed using a lysis buffer consisting of
PBS +0.5% NP40 + protease inhibitors (aprotin-100mM,
leupeptin-20mM, pepstatin-20mM, PMSF-400mM). RNAwas
isolated from cell lysates using TRIzol RNA isolation protocol
(Ambion) following the manufacturer’s direction. RNA con-
centration was measured using a NanoDrop 2000 spectro-
photometer. cDNA reverse transcription was performed using
Improm-II RTase reagents (Promega). qPCR was run using
*50ng cDNA per reaction with 2·SYBR qPCRmaster mix,
and primers for Malat-1 (Forward–5¢-AAAGCAAGGTCT
CCCCACAAG-3¢, Reverse- 5¢-TGAAGGGTCTGTGCTAG
ATCAAAA-3¢) (Eurofins), and beta-actin control (Forward-
5¢-AAGTCAGTGTACAGGTAAGCC-3¢, Reverse- 5¢-GTC
CCCCAACTTGAGATGTATG-3¢) (IDT). Samples were run
in at least triplicate for statistical analysis on a Bio-Rad CFX
Connect qPCR machine, using the following cycling proto-
cols: 10min at 50C, 5min at 95C, and 40 cycles of 15 s at
95C and 1min 15 s at 60C. Primer specificity was verified by
using a melt curve analysis after PCR analysis was performed.
Cq values were determined using Bio-Rad the CFX manager
software. RNA levels of the controls were compared with that
of Malat-1 (PS-ASO target) by determination of the relative
quantity from the beta-actin control; afterward the relative
quantities were normalized to non-PS-ASO-treated controls
for each sample to generate reported gene expression levels
for each RNA target. Statistical analysis was done by using a
Student’s t-test for pairwise comparison usingMicrosoft Excel.
Overexpression of LBPA by DHA induction
Lysobisphosphatidic Acid (LBPA) cannot be directly in-
duced into mammalian cells; therefore, the lipid precursor
docosahexaenoic acid (DHA) was used. Working stock solu-
tions of DHA (50.0mM in ethanol) and lipid-free bovine serum
albumin (BSA; 5mM in water) were mixed at a 4:1 ratio,
respectively. The solution was diluted to a working solution of
10.0mM DHA that has been reported to a working concentra-
tion for overexpression of DHA (and by conversion of LBPA)
without leading to cytotoxic effects on the cells. Cells were first
treated with siRNAs for RAB7A, EEA1, or scrambled siRNA
for 24 h to provide proper target knockdown. The cells were
then incubated in 10.0mMDHA-BSA DMEM. Given the cells
inability to survive long term in BSA media, a 6-h incubation
forDHAmedia was done with or without PS-ASO contained in
themedia. This should not have any impact on PS-ASO activity
as these molecules have shown transport to LE/lysosome at
3–6 h [6]. After 6 h of DHA-BSA–PS-ASO media, cells were
harvested and qPCR analysis was done forMalat-1 expression
(see ‘‘Purification of RNA and qPCR analysis section’’).
Rab5C overexpression and Western blot analysis
The Rab5 plasmid (OriGene NM_201434) was transiently
transfected into 190-kDa HARE-overexpressing cells using
Lipofectamine 2000 under predetermined optimal condi-
tions. Cells were treated for 24, 48, and 72 h to determine if
transfection was possible for qPCR analysis with siRNA and
PS-ASO treatment to follow. Cell lysates were separated by
10% SDS-PAGE using 30 mg of protein, blotted, and probed
with a mouse monoclonal anti-DDK primary antibody (Ori-
Gene), followed by an anti-mouse fluorescence secondary
antibody (LiCor). After overexpression levels were verified
by western blot, a transient transfection of Rab5C using Li-
pofectamine 2000 was performed and incubated for 24 h
before siRNAs were added, followed by PS-ASO incubation.
A qPCR analysis was performed targeting Malat-1.
Rab5C (S35N) point mutant
The Rab5C plasmid from OriGene was subject to site-
directed mutagenesis (serine to asparagine substitution) using
Q5 (New England Biolabs) reagents. Primers used were:
Forward–5¢-GTAGGCAAAAACAGCCTCGTCCTCCGCT
TTG-3¢, Reverse–5¢-CGAGGCTGTTTTTGCCTACCGCA
GACTCC-3¢ (Eurofins). Rab5C plasmid was PCR amplified
using Q5-HiFi Polymerase (NEB) for 18 cycles. Samples
were Dpn1 digested for 1 h to remove methylated template
DNA, and heat shock transformed into competent Escher-
ichia coli cells. Cells were plated, grown, and screened for
correct sequence. Rab5CS35N plasmids were transfected
into 190-HARE cells and incubated for 24 h, followed by
siRNA treatment. After 24 h of siRNA treatment, PS-ASOs
(0.1 mM) were added and incubated for 24 h, followed by
qPCR targeting Malat-1 as described above.
Labeling and endocytosis of hyaluronan and ASOs
Approximately 100mg of hyaluronan (HA) with an average
size of 130 kDawas labeledwith a Bolton-hunter adduct on the
reducing end of the polymer using the method of Raja et al.
[22]. The Bolton-hunter adduct is iodinated with 0.3 mCi
carrier-free 125I-Na (MPBio) and the HA is quantified using
the carbazole assay [23]. For the HA endocytosis assays, cells
were plated at least 2 days before the assay and allowed to
grow up to about 80% confluence in 24-well polystyrene tissue
culture plates. Endocytosis mediumwas preparedwithDMEM
supplemented with 0.05% BSA and 1mg/mL 125I-HA alone or
with 100mg/mL unlabeled HA to serve as a nonspecific uptake
control. Cells were incubated with the HA ligands for 2 h,
washed three times with ice-coldHank’s Balance Salt Solution
(HBSS) and cell lysates were prepared with 0.3mL 0.3M
NaOH. Counts per minute (CPM) of each lysate was measured
with a Wallac 1470 Wizard Gamma Counter and total protein
was measured by the Bradford assay.
Specific endocytosis of HA was calculated by subtracting
the 125I-HA +HA samples from the 125I-HA samples. For the
ASO endocytosis assays, 125I-streptavidin (SA) was prepared
by the method of Harris et al. [7] and mixed in a 1:4 ratio with
bASO. An equivalent amount of 100 nM 125I-SA-bASO or
125I-SA alone was incubated with prepared cells for 6 h,
washed, and prepared in the same manner as the HA uptake
described above. Specific endocytosis of ASO was measured
by subtracting the 125I-SA alone values from the 125I-SA-
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bASO values. Nonspecific binding of 125I-HA + HA was less
than 3% 125I-HA and 125I-SA was less than 1% of the 125I-
SA-bASO. Each experiment was performed at least twice
with at least three replicates per sample.
Statistics
All experiments were performed at least three times with
three replicates per experiment. The mean of each experiment
was calculatedwith standard deviation. Groups of experimental
data were compared using the Student’s t test with a p-value
equal to or less than 0.05 considered significantly different.
Results
ASO chemistry and design
A second-generation PS-ASO targeting the long noncoding
RNA Malat-1 was used for our experiments. Gen 2 PS-ASOs
have a central DNA region that is flanked on both ends with a
2¢-O-methoxyethyl RNA (MOE) modification. The DNA gap
promotes degradation of the targeted RNA by RNaseH1-
mediated hydrolysis. RNaseH1 is a ubiquitously expressed
endonuclease, which selectively degrades the RNA strand of a
DNA–RNA heteroduplex. The 2¢MOE modifications work to
increase metabolic stability of these PS-ASOs, while also in-
creasing the affinity of target binding. The knockdown of
Malat-1, as measured by quantitative RT-PCR (qRT-PCR),
was used as a surrogate for PS-ASO escape from the en-
dosomal compartments as RNA knockdown can only occur
when PS-ASO is released from these compartments [24,25].
Early endosome versus LE targets
Once internalized by the Stabilin receptors into clathrin-
coated vesicles, PS-ASOs are trafficked to the lysosome for
degradation [6]. However, at some point in the endosomal
trafficking pathway, a fraction of the internalized PS-ASO
has to escape these vesicles and enter the cytoplasm and/
or the nucleus to induce RNase H-mediated degradation
ofMalat-1. Early endosome antigen 1 (EEA1), a peripheral
hydrophilic membrane protein found in early endosomal
membrane fractions as well as in the cytosol, was selected
as a possible candidate for screening [12]. EEA1 is involved
in early endosomal vesicle transport for fusion with LEs
through SNARE proteins, as well as early endosome sorting
[26,27]. With regard to LEs, the small GTPase Rab7A, which
plays an important role in a variety of LE functions, in-
cluding motility, biogenesis, cargo transport, among many
others, was chosen as a potential candidate affecting PS-ASO
release [17,19,28].
After verifying siRNA functionality for target RNA
knockdown (Supplementary Fig. S2), cells were incubated in
5.0 pmol siRNA for EEA1 or Rab7A, followed by PS-ASO
incubation for 24 h. This was done to determine if knock-
down of specific proteins in the early or LE affectedMalat-1
expression as a measure of PS-ASO release. From our results,
cells left untreated (Fig. 2A) or treated with a scrambled
negative control siRNA (Fig. 2B) showed significant PS-
ASO activity for reducing Malat-1 RNA expression. How-
ever, when EEA1 siRNA (Fig. 2C) or Rab7A siRNA
(Fig. 2D) was added to cells, expression levels of Malat-1
were not affected and no different than paired samples that
were not treated with PS-ASO. Given that EEA1 and Rab7A
are in two separate maturation stages of the endosomal
pathway, this suggested that PS-ASO activity is a result of
endosomal escape before transport to the lysosome. The re-
sults also provided evidence that these proteins could be
working in conjunction through the same mechanism to in-
fluence PS-ASO release.
FIG. 2. Knockdown of specific targets by
siRNA treatment followed by treatment of
0.1 mM PS-ASO against Malat-1 with rela-
tive quantities was normalized. Following
RNA extraction, cDNA synthesis was per-
formed and normalized to *50 ng/reaction.
Expression of Malat-1was assessed by
SYBR green qPCR amplification with beta-
actin controls in cells with (A) no siRNA
treatment, (B) a negative control scrambled
siRNA, (C) siRNA for EEA1, (D) siRNA
for RAB7A. Bars represent normalized
Malat-1 expression as mean – standard de-
viation, n= 3. Statistical analysis was per-
formed using two-tailed Student’s t-test
P < 0.05. EEA1, early endosomal antigen 1.
NS, not statistically significant.
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Rab5 isoforms alter PS-ASO activity
A potential molecular pathway that regulates early en-
dosomal trafficking and is known to interact with EEA1 is
Rab5 [27], which is expressed in cells in three distinct iso-
forms: Rab5A, Rab5B, and Rab5C. These isoforms share a
sequence homology of roughly 90%; however, Rab5A and
5B are functionally different from Rab5C due to each iso-
form’s respective ability to interact with different effector
proteins, such as Rab5C, being the only isoform shown to
interact with Rac1 [14,29]. Each isoform of Rab5 was dis-
rupted in our 190-HARE-overexpressing cells by siRNA
knockdown, which was verified by qPCR analysis (Supple-
mentary Fig. S3). After siRNA induction, cells were treated
with 0.1 mM of PS-ASO against Malat-1 to determine if any
knockdown of a specific isoform influenced PS-ASO release.
Untreated siRNA controls (Fig. 3A), as well as scrambled
siRNA (negative) controls (Fig. 3B) were carried out
to demonstrate that the PS-ASO was functional. Rab5A and
Rab5B followed a similar pattern to the controls, indicating
no functional role in altering PS-ASO activity (Fig. 3C, D).
However, when Rab5C expression was inhibited by siRNA,
no knockdown of Malat-1 was observed, indicating that
Rab5C is working in conjunction with EEA1 to facilitate
PS-ASO escape from endosomes and/or PS-ASO trafficking
from early to LEs (Fig. 3E). To ensure that our methods
were not perturbing Stabilin-2-mediated endocytosis or other
mechanisms of ASO internalization, we treated 190-HARE
cells with all of the siRNAs individually followed by the
addition of radiolabeled PS-ASO. The effect of siRNA
treatment with these cells did not affect PS-ASO uptake
(Fig. 4A) nor did it affect other ligands for Stabilin-2 such as
hyaluronan (Fig. 4B).
DHA-supplemented medium alters PS-ASO activity
A recent report indicated that LPBA is a molecular com-
ponent of endosomal escape in cell lines that are amenable for
FIG. 3. Malat-1 expression was analyzed
through qPCR based on RAB5 knockdowns
by siRNA, followed by treatment with
0.1 mM PS-ASO against Malat-1. cDNA was
normalized to *50 ng/reaction. Expression
of Malat-1assessed by SYBR green qPCR
amplification with beta-actin controls in
cells (A) with no siRNA treatment, (B)
treated with a negative control scrambled
siRNA, (C) treated with siRNA for RAB5A,
(D) treated with siRNA for RAB5B, (E)
treated with siRNA for RAB5C. Bars rep-
resent normalized Malat-1 expression as
mean – standard deviation, n = 3. Statistical
analysis was performed using two-tailed
Student’s t-test P< 0.05.
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PS-ASO activity through free uptake [21]. LBPA has previ-
ously been reported to be enriched in late endosomal vesicles,
whereas also being reported to be required to assist is en-
dosomal escape for PS-ASOs within the LE [21,30]. LPBA
cannot be simply incorporated into cells in its active form. A
method for LPBA overexpression in mammalian cells is to
incorporate 10.0 mM docosahexaenoic acid (DHA) as a
starting substrate that has been shown to be converted to
LBPA [31]. Replicating this method in our cell lines proved
to be successful and an increase in LBPA was detected by an
anti-LBPA antibody as previously reported [21] (Supple-
mentary Fig. S4A, B). The 190-HARE-overexpressing cells
were supplemented with 10.0 mMDHA conjugated with BSA
in the medium, followed by treatment with siRNA for en-
dosomal protein knockdown, followed by PS-ASO treatment.
In our non-siRNA untreated controls, as well as scrambled
siRNA (negative) controls, a similar trend of PS-ASOs fa-
cilitatingMalat-1 knockdown was noticed, which was on par,
or further knocked down by DHA medium supplementation
(Fig. 5A, B). However, for EEA1 knockdown, the incorpo-
ration of DHA was able to rescue PS-ASO activity, shown by
Malat-1 knockdown (Fig. 5C). Interestingly, when Rab7A
was knocked down, the supplementation of LBPA was un-
able to rescue the effects of PS-ASO activity, pointing
to Rab7A as the limiting factor in late endosomal PS-ASO
transport (Fig. 5D). The knockdown of Rab7A in addition
to the isoforms of Rab5 and EEA1 did not affect degradation
of Stabilin-2 ligands. Since we could not measure degra-
dation of the PS-ASO molecule efficiently, we monitored
125I-hyaluronan degradation under each siRNA treatment and
found that degradation for all conditions was not affected
(Supplementary Fig. S5). Therefore, the integrity of the early
and late endosomal pathway was intact despite manipulations
in EEA1, Rab7A, and LBPA levels.
Rab5C overexpression leads to increased
PS-ASO activity
Given the importance of Rab5C to modulate PS-ASO ac-
tivity by activating EEA1 for endosomal fusion, we exam-
ined the effect of overexpressing Rab5C. A Rab5C plasmid
was transiently transfected into cells for 24, 48, and 72 h to
determine if production would be substantial in our 190-
HARE cells over 72 h. As shown by western blot analysis,
overexpression of Rab5C peaked at 72 h posttransfection
(Fig. 6A). It was verified that 72 h was sufficient for Rab5C
expression in cells. The 190-HARE cells were transfected
with Rab5C, followed by an incubation with siRNAs for
EEA1 and Rab7A at 24 h postinduction. This was followed
by PS-ASO treatment 24 h post siRNA induction, and was
incubated for a final 24 h followed by cell lysis. WhenMalat-
1 levels were analyzed in our control cells, PS-ASO activity
was unchanged and similar to previous controls (Fig. 6B, C).
When EEA1 was knocked down, overexpressing Rab5C was
not able to overcome the absence of its interacting partner, as
Malat-1 levels were that of non-PS-ASO-treated control cells
(Fig. 6D). Interestingly, in the Rab7A knockdown cells, PS-
ASO activity was restored (Fig. 6E), as higher levels of
Rab5C are able to increase ability of Rab5-Rab7 exchange
and Rab5 becomes displaced from the endosome concomi-
tantly by the addition of Rab7A [32].
Dominant negative Rab5C expression
alters PS-ASO activity
To determine if Rab5C activity was a crucial driving force
for PS-ASO activity, a S35N substitution was created in
the GTP-binding site leading to a dominant negative protein.
The dominant negative Rab5C was then transiently over-
expressed in 190-HARE cells and verified by western blot
analysis (Fig. 7A). This confirmed that the expression of the
inactive mutant is sufficient over the time course of treatment
similar to the Rab5C overexpression experiment. The cells
were then treated in a similar fashion to our previous Rab5C-
overexpressing cells with siRNA knockdowns for EEA1 and
Rab7A, followed by incubation of PS-ASOs againstMalat-1.
The results from the untreated and negative control (scram-
bled) siRNA samples indicated that the dominant negative
Rab5C ablated PS-ASO activity as Malat-1 expression was
not inhibited (Fig. 7B, C). Similarly, when siRNA treatments
were induced for EEA1 and Rab7A, followed by PS-ASO
induction, there was no significant change in Malat-1 ex-
pression (Fig. 7D, E). These results provide evidence that
FIG. 4. siRNA targeted knockdown of individual proteins
had no effect on endocytosis of I125 radiolabeled ligands.
Cells were grown to 50% confluency and then treated with
siRNAs as indicated. Twenty-four hours posttreatment, cells
were washed and treated with radiolabeled (A) PS-ASO or
(B) HA for 6 h and 2 h, respectively. The background con-
trol for PS-ASO uptake was free 125I-SA, which was not
conjugated to the PS-ASO and the control for the HA uptake
were cells incubated with 100-fold excess unlabeled HA.
Bars represent CPM normalized to protein concentration
with mean – standard deviation, n = 3. Scr. siRNA is a neg-
ative control for siRNA induction. Statistics used two-tailed
Student’s t-test, P < 0.05.
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FIG. 5. Malat-1 expression analyzed
through qPCR based on PS-ASO against
Malat-1 in conjunction with siRNA treat-
ment and DHA media supplementation for
LBPA overexpression analysis. cDNA was
normalized to *50 ng/reaction. Expression
of Malat-1assessed by SYBR green qPCR
amplification with beta-actin controls. (A)
Expression of cells with no siRNA treatment,
(B) Expression of cells treated with a nega-
tive control scrambled siRNA, (C) Expres-
sion of cells treated with siRNA for EEA1,
(D) Expression of cells treated with siRNA
for RAB7A. Bars represent normalized
Malat-1 expression with mean – standard
deviation, n = 3. Statistical analysis was
performed using two-tailed Student’s t-test
P < 0.05.
FIG. 6. Malat-1 expression based on PS-
ASO against Malat-1 in conjunction with
RAB5C overexpression and siRNA treatment.
qPCR analysis performed by SYBR green
qPCR amplification with beta-actin controls
with cDNA normalized to *50ng/reaction.
(A) Western blot of transient transfection us-
ing varied Lipofectamine concentrations over
multiple time points, (B) Expression of cells
with no siRNA treatment, (C) Expression of
cells treated with a negative control scrambled
siRNA, (D) Expression of cells treated with
siRNA for EEA1, (E) Expression of cells
treated with siRNA for RAB7A. Bars repre-
sent normalized Malat-1 expression with
mean– standard deviation, n= 3. Statistical
analysis was performed using two-tailed Stu-
dent’s t-test P< 0.05.
92 MILLER ET AL.
Rab5C activity is important for PS-ASO escape from en-
dosomal compartments.
Discussion
In this study, we report that specific trafficking molecules
in the early and late endosomal pathway affect PS-ASO ac-
tivity startingwith initial uptake by the Stabilin-2 (190-HARE)
receptor (Fig. 8). We discovered that knockdown of EEA1
and Rab7A reduces PS-ASO efficacy without affecting bulk
ASO internalization in Stabilin-2-overexpressing HEK cells.
Somewhat surprisingly, the knockdown of Rab5C or over-
expressing the dominant negative Rab5C also reduced the
ASO activity.
Nearly two decades ago, it was discovered that early en-
dosomes are quite heterogeneous depending on receptors,
FIG. 7. Dominant negative RAB5C trans-
fection of 190-HARE-overexpressing cells.
qPCR analysis performed by SYBR green
qPCR amplification with beta-actin controls
with cDNA normalized to *50ng/reaction.
(A) Western blot showing inactive mutant
expression 72h posttransfection (lane 1) and
untransfected cells (lane 2), (B) Expression of
cells with no siRNA treatment, (C) Expres-
sion of cells treated with a negative control
scrambled siRNA, (D) Expression of cells
treated with siRNA for EEA1, (E) Expres-
sion of cells treated with siRNA for RAB7A.
Bars represent normalized Malat-1 expres-
sion with mean– standard deviation, n= 3.
Statistical analysis was performed using two-
tailed Student’s t-test P< 0.05.
FIG. 8. Schematic repre-
sentation of interacting part-
ners from early endosome–late
endosomal fusion. Rab5C in-
teracts with EEA1 to allow
for endosomal maturation and
fusion with a late endosome.
The late endosome facilitates
Rab7A to interact with LBPA,
which is involved in PS-ASO
escape. Rab5C and EEA1 are
returned back to the early en-
dosome by a vesicle, as they
remain membrane tethered.
LBPA, lysobisphosphatidic
acid.
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cargo, and intracellular components. A single early en-
dosomal vesicle may be a mosaic of different biochemical
domains that split off and mature as single entities [33]. It is
possible that RabCmay cluster to form an enriched domain to
sequester Stabilin-2 and its cargo for trafficking to the LE.
Rab GTPases undergo specific spatial organization and dis-
tribution, allowing for vesicle motility, formation, and fusion
[34]. Specific compartmentalization of enriched membrane
domains induces cooperativity, facilitating spatial segrega-
tion for different cargos. The identification of Rab5 as an
activator of EEA1 through a zinc finger binding domain has
been well established [35]; however, the identification of the
specificity for the Rab5C isoform with regard to regulation of
PS-ASO transport helps provide insight into the mechanism
behind PS-ASO escape and activity. Although previous
works have identified possible mechanisms for endosomal
escape of PS-ASOs, this article provides specific molecular
manipulations and interactions for the mechanism underlying
the proposed escape pathway [2,36,37].
As PS-ASOs are trafficked through the endosomal pathway
after receptor mediated endocytosis, they are subsequently
transported through the LE/multivesicular body to the lyso-
some for degradation. During transport to the LE, Rab7A in-
teracts with the phospholipid LBPA, which is a component in
other late endosomal processes such as protein trafficking and
cholesterol transport [38,39]. LBPA has been previously
shown to have a role in the escape of PS-ASOs [21] and other
cargos such as vesicular stomatitis virus nucleocapsids and
anthrax toxin from late endosomal compartments [40]. LBPA-
containing MVB/LEs represent a subpopulation containing
ubiquitinated membrane proteins [41] suggesting that a higher
proportion of PS ASOs are transported to LBPA-containing
vesicles after Stabilin-mediated internalization. In addition,
recent work has identified that the cytosolic autophagy protein,
Alix, alters levels of LBPA [5,21]. Alix has also been reported
to be involved in the regulation of the endolysosomal system
[42]. These results demonstrate that modulating LBPA and
Rab7A affects activity of PS-ASOs and suggests that escape of
PS-ASOs occurs as a late endosomal event before trafficking
to the lysosome.
Stabilin-2 (190-HARE) internalizes a wide variety of
negatively charged molecules ranging from sizes of polymers
of several hundred kDa (Hyaluronan) down to oligos of a 20+
nucleotides (PS-ASOs) [6,43]. Although not much is known
about Rab5C, it has previously been identified to operate
independently of Rabs 5A and 5B in the trafficking and
signaling of the EGF receptor [14,29]. EGF receptors are
dependent on Rab5A for internalization and degradation,
whereas, we did not see the same effect on the internalization
for Stabilin-2. The fact that knocking down Rab5C ablated
the function of the PS-ASO cargo suggests that Rab5C, and
not Rabs 5A or 5B, is essential for downstream trafficking of
this cargo. It remains unknown if Rab5C is only involved in
trafficking of PS-ASO cargo or if other Stabilin-2 cargos use
the same trafficking mechanism. We previously reported that
Stabilin-2 is a signaling receptor [44] and that downstream
signaling is cargo dependent [8], which may have further
implications into how the receptor is trafficked depending on
the bound cargo.
Efficacy of a therapeutic ASO targeted against a specific
RNA for either systemic or tissue-specific knockdown of
gene expression is dependent on several factors, including
initial dose, site of injection (subcutaneous, intravascular,
intrathecal, etc), clearance rates by liver and kidney, inter-
nalization by the target tissue, and escape from the endosomal
pathway [45]. The physicochemical principles for designing
an ASO to remain intact in biological fluids and for enhancing
binding to its target RNA are relatively well understood. The
difficulty lies in the delivery of the ASO to target tissues/cells
and allowing an effectual number of the ASOs to pass bio-
logical barriers in the form of membranes and lysosomes.
We previously reported that both Stabilin-1 and Stabilin-2
receptors are specific endocytic receptors for nontargeted PS-
ASOs with high affinity and endocytic activity. Although
Stabilin receptors are highly expressed in specific tissues
such as in the sinusoids of liver, lymph node, spleen, and bone
marrow [11,46], it is becoming evident that their expression
is more widespread than previously thought by more recent
reports [47,48]. Both receptors are internalized by classic
clathrin-mediated mechanisms [49] that result in the majority
of ligand to be degraded in lysosomes for anabolic cellular
functions. Any additional knowledge about how ASO-
binding receptors are trafficked through the cells of targeted
and nontargeted tissues is of therapeutic value as their
mechanisms may be exploited to increase delivery efficiency.
Conclusion
After internalization by Stabilin receptors, PS-ASOs are
transported in the classical Rab5-mediated endosomal route.
As the transition from early to LEs occurs, EEA1 is activated
by Rab5C to facilitate vesicle fusion. The majority of inter-
nalized PS-ASO is trafficked to the lysosome for degradation,
with a small fraction escaping from the LE. Escape is facil-
itated by Rab7 and LBPA in the LE, allowing for the in-
creased release of PS-ASO molecules into the cytosol and
nucleus for exerting antisense effects.
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